Biomarker-Guided Adjuvant Treatment Supports Real-World Survival in Early NSCLC
Biomarker-targeted adjuvant therapy improved survival in early-stage NSCLC, highlighting the importance of testing and reducing treatment disparities.
Jun 10, 2025
MEETING BRIEF
ASCO 2025 – eNSCLC
The latest news from ASCO 2025 focusing on eNSCLC including abstracts, features, and helpful conference information.
‘Spread Through Air Spaces’ Predicts Poorer Prognosis in Stage 1 EGFR-Mutant Lung Adenocarcinoma
‘Spread Through Air Spaces’ Predicts Poorer Prognosis in Stage 1 EGFR-Mutant Lung Adenocarcinoma
Data from ASCO 2025 shows spread through air spaces has emerged as a powerful predictor of poor outcomes in stage 1 EGFR-mutant lung cancer, revealing aggressive molecular traits that could reshape future risk stratification and treatment decisions.
In Early NSCLC, Molecular Testing Rates Improve With EMR Nudge
In Early NSCLC, Molecular Testing Rates Improve With EMR Nudge
An EMR-based prompt significantly boosted molecular testing rates and detection of actionable mutations in early-stage, non-squamous NSCLC post-surgery.
Early NSCLC at ASCO: Evaluating New Assay & Treatment Patterns
Early NSCLC at ASCO: Evaluating New Assay & Treatment Patterns
New ASCO data highlight presurgical ctDNA as a relapse predictor in early NSCLC and show surgery improves survival over radiation among veterans.
Which session are you most looking forward to attending at ASCO?
Which session are you most looking forward to attending at ASCO?
Share your thoughts! Which session are you most looking forward to attending at ASCO?
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
